Company Profile

Genmab AS (NASDAQ: GMAB)
5:00 PM UTC, 07/03/24
Last: $25.15 Change: +0.25 %Change: +1.00% Volume: 236,520
Detailed Quote
Open: $ 25.10   Volume: 236,520
High: $ 25.27   Yield(%) 0.00
Low: $ 25.08   P/E Ratio (ttm): 20.47
Dividend ($): n/a   Market Cap ($): 16.22B
EPS ($) 1.22   Shares Out: 651.55M
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): -12.63
% Price Change (last 13 weeks): -16.89
% Price Change (last 26 weeks): -22.45
% Price Change (last 52 weeks): -34.75
% Price Change (year to date): -21.80
Management Effectiveness
Return on Equity (%): 14.65
Return on Assets (%): 13.19
Return on Invested Capital (%): 19.27
Profitability
Gross Profit Margin (%): 96.64
Net Profit Margin (%): 26.42
Operating Profit Margin (%): 32.30
Price & Volume
50-day Moving Average: $27.88
200-day Moving Average: $30.04
Avg. Daily Vol. (last 50 days): 532,124
Avg. Daily Vol. (last 200 days): 654,367
52-wk high: $42.72
52-wk low: $24.53
Bid: $25.20
Ask: $26.00
Company Information
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Genmab AS
Carl Jacobsens Vej 30 Valby
Copenhagen CD 2500

Phone: 45.70.20.27.28
Fax: n/a
http://www.genmab.com
Per Share Data
Earnings (1year) ($): 1.22
Annual Dividend ($): 0.00
Current P/E Ratio (ttm): 20.47
Book Value ($): 7.17
Cash Flow ($): 1.04
Valuation Ratios
Price/Earnings (x): 20.47
Price/Sales (x): 8.78
Price/Book (x): 4.44
Price/Cash Flow (x): 19.60
Financial Strength
Quick Ratio (x): 13.32
Current Ratio (x): 13.34
LT Debt/Equity (x): 2.15
Total Debt/Equity (x): 2.44



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2020 Wall Street Horizon, Inc.